AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37818791
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care interventions delivered by healthcare professionals (general physicians, pharmacists, nurses, geriatricians)
Trial: 37819503
Drug: Proposed adaptive
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed adaptive dosing strategy
Trial: 37819505
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg every 4 weeks (Q4W) or at week 0, week 4, then Q8W
Trial: 37819691
Drug: Standard ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ICI therapy (control group)
Trial: 37819936
Drug: Low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemcitabine (100 mg/m2 on days 1, 8, and 15) combined with CHK1 inhibitor LY2880070 (50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle)
Trial: 37820029
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg followed by placebo
Trial: 37820029
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg followed by placebo
Trial: 37820358
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (10 participants)
Trial: 37821096
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg CBD (0:1 CBD:THC)
Trial: 37821096
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CBD (1:1 CBD:THC)
Trial: 37821096
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBD (2:1 CBD:THC)
Trial: 37821096
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg CBD (3:1 CBD:THC)
Trial: 37821122
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided deposit lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (lavage+steroid)
Trial: 37821122
Drug: Sham lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (sham lavage+steroid)
Trial: 37821122
Drug: Sham lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham lavage plus subacromial injection of 10 mL 1% lidocaine hydrochloride (sham)
Trial: 37821131
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg potassium canrenoate every 6 hours until organ procurement
Trial: 37821242
Drug: Metastasis-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis-directed therapy (MDT) and 6 months of androgen deprivation therapy (ADT)
Trial: 37821342
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at ZT8
Trial: 37821342
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion at ZT8
Trial: 37821461
Drug: Antipsychotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics plus metformin
Trial: 37821461
Drug: Antipsychotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics alone
Trial: 37821472
Drug: Latency-reversing agent
RxNorm normalized name: Reversion Acne Control Toner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latency-reversing agent vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv vaccines
Trial: 37821913
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention based on Cognitive Behavior Therapy
Trial: 37821968
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous oxygen saturation (ScvO2)-based goal-directed therapy
Trial: 37821968
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid loading-based goal-directed therapy
Trial: 37822243
Drug: Low-molecular-weight fucoidan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight fucoidan (LMF) as a supplement to therapy.
Trial: 37822710
Drug: Exercise (60-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (60- to 75-min daily)
Trial: 37823031
Drug: TransCon CNP
RxNorm normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon CNP 100 μg CNP/kg/week
Trial: 37823034
Drug: TV-46046 (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-46046 (120 mg/0.3 mL)
Trial: 37823034
Drug: Depo-subQ Provera
RxNorm normalized name: depo-subQ provera
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-subQ Provera 104 (104 mg/0.65 mL)
Trial: 37823034
Drug: Diluted TV-46046
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted TV-46046 (60 mg/0.3 mL)
Trial: 37823034
Drug: TV-46046 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-46046 placebo (0.3 mL)
Trial: 37823722
Drug: Fingolimod treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod treatment
Trial: 37823971
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 IU/ml)
Trial: 37824131
Drug: Intratumoral GLA-SE
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral GLA-SE (5 μg and 10 μg for 8 weekly doses) with concurrent radiotherapy
Trial: 37824131
Drug: Intratumoral GLA-SE
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral GLA-SE with concurrent radiotherapy
Trial: 37824137
Drug: Topotecan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan alone (1.25 mg/m2 intravenously on days 1 through 5)
Trial: 37824137
Drug: Topotecan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan with berzosertib (210 mg/m2 intravenously on days 2 and 5)
Trial: 37824155
Drug: Cryoprecipitate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate (3 pools, 6-g fibrinogen equivalent) administered within 90 minutes of randomization and 3 hours of injury, in addition to standard care.
Trial: 37824754
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy
Trial: 37826937
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg caffeine
Trial: 37826937
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg caffeine
Trial: 37827268
Drug: Cabergoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (1 mg once on postpartum day 1 or 0.25 mg twice a day for 2 days)
Trial: 37827268
Drug: Pyridoxine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (200 mg 3 times a day for 7 days)
Trial: 37827280
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose and treatment volume
Trial: 37827744
Drug: Patient-led home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-led home-based surveillance after curative CRC treatment.
Trial: 37828033
Drug: Sintilimab (anti-PD-1)
RxNorm normalized name: Dianeal PD-2/1.5
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (anti-PD-1) at doses of 1, 3, and 10 mg/kg
Trial: 37828034
Drug: ZSP1601 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 50 mg once daily
Trial: 37828034
Drug: ZSP1601 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 50 mg twice daily
Trial: 37828034
Drug: ZSP1601 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 100 mg twice daily
Trial: 37828071
Drug: Diabetes mellitus
RxNorm normalized name: diagnostic,monitoring agents for diabetes mellitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes mellitus severity and treatment regimen (oral medication vs insulin vs both oral + insulin)
Trial: 37828071
Drug: LDL <
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LDL < 100 mg/dl
Trial: 37828470
Drug: Clinical assessment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical assessment, chest X-ray, and comprehensive lung function assessment at treatment completion and again six and 12 months later.
Trial: 37828564
Drug: Group Physical
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Physical Therapy Program for Knee OA (Group PT) with tailored, high-touch support (enREP)
Trial: 37828564
Drug: Group Physical
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Physical Therapy Program for Knee OA (Group PT) with standard, low-touch support (REP)
Trial: 37828618
Drug: Enhanced therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced therapy (personalized treatment approach including pressure-optimized custom-made footwear, at-home daily foot temperature monitoring, structured education)
Trial: 37830579
Drug: Mitazalimab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitazalimab (600 µg/kg and 900 µg/kg administered intravenously)
Trial: 37830908
Drug: mRNA-1273 (Moderna)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine
Trial: 37831074
Drug: Continuous anti-IL-6R
RxNorm normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous anti-IL-6R therapy
Trial: 37831433
Drug: New prognostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prognostic model based on four variables: past deterioration, neutrophil proportion > 70%, Na < 128 mmol/L, and vasopressor use.
Trial: 37831485
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or CAS
Trial: 37832758
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg once daily for 6 months
Trial: 37833472
Drug: Hydromorphone 2
RxNorm normalized name: HYDROmorphone 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 2 mg given six hours after interscalene block
Trial: 37833472
Drug: Hydromorphone 2
RxNorm normalized name: HYDROmorphone 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 2 mg and Placebo
Trial: 37833493
Drug: HSK21542 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK21542 (2 μg/0.212 μCi/kg)
Trial: 37833679
Drug: Liberalized potassium
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberalized potassium diet (3500 mg dietary K daily)
Trial: 37833679
Drug: Standard potassium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard potassium restricted diet (<2000 mg dietary K daily)
Trial: 37834761
Drug: Tegoprazan 50
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 50 mg daily
Trial: 37835071
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) combined with B-cell depletion therapy
Trial: 37837376
Drug: Immunotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy regimen during ATI
Trial: 37837942
Drug: Treatment strategies
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategies at t0 (time of active suicidal ideation with intent)
Trial: 37837989
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy with medical treatment
Trial: 37837989
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (standard of care)
Trial: 37838323
Drug: Small-bowel capsule
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-bowel capsule endoscopy (SB-CE)
Trial: 37838604
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (1000 mg i.v. administered 24-72 hours before surgery)
Trial: 37838604
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered 24-72 hours before surgery)
Trial: 37838623
Drug: SHR7280 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7280 (200 mg QD, 300 mg QD, 200 mg BID)
Trial: 37838686
Drug: Handgrip strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handgrip strength (HGS) during chemotherapy
Trial: 37838686
Drug: Minnesota Manual
RxNorm normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnesota Manual Dexterity Test (MMDT) during chemotherapy
Trial: 37838686
Drug: European Organization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Module Cancer Related Fatigue (EORTC-QLQ-FA12) during chemotherapy
Trial: 37838686
Drug: Semmes Weinstein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semmes Weinstein Monofilament Test (SWMT) during chemotherapy
Trial: 37838987
Drug: Trifarotene 50
RxNorm normalized name: Trifarotene 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifarotene 50 μg/g
Trial: 37839707
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400 mg/d)
Trial: 37839958
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) - 10 weekly sessions of 120 minutes each
Trial: 37840119
Drug: Spesolimab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab (900 mg, single intravenous dose on day 1)
Trial: 37840134
Drug: sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarilumab 200 mg (SAR200 + 26W)
Trial: 37840134
Drug: sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarilumab 150 mg (SAR150 + 26W)
Trial: 37840134
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with 52-week GC taper (PBO + 52W)
Trial: 37840134
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with 26-week GC taper (PBO + 26W)
Trial: 37840155
Drug: Danuglipron (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron (20 mg)
Trial: 37840530
Drug: Abemaciclib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib monotherapy
Trial: 37840530
Drug: SOC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC chemotherapy (gemcitabine or capecitabine)
Trial: 37840766
Drug: 1.5% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% ruxolitinib cream applied to lesions once or twice daily for 52 weeks
Trial: 39418346
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus an aromatase inhibitor (AI)
Trial: 37842323
Drug: shen-based qigong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shen-based qigong exercise intervention along with daily rehabilitation
Trial: 37842323
Drug: daily rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily rehabilitation
Trial: 37843771
Drug: Tirzepatide 5
RxNorm normalized name: tirzepatide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 5 mg, 10 mg, 15 mg
Trial: 37843843
Drug: Resveratrol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplementation (400 mg/d for 6 weeks)
Trial: 37844137
Drug: SAVAL self-expandable
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SAVAL self-expandable paclitaxel drug-eluting stent (DES)
Trial: 37844597
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (240 mg IV every 2 weeks)
Trial: 37844597
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (3 mg/kg and 1 mg/kg respectively) boosts
Trial: 37844598
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenous once every 3 weeks plus lenvatinib 20 mg oral once per day for up to 2 years or until disease progression, development of unacceptable toxicity, or withdrawal of consent.
Trial: 37844986
Drug: OCA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA group (oxycodone: 0.5 mg/kg)
Trial: 37844986
Drug: OCB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCB group (oxycodone: 1.0 mg/kg)
Trial: 37844986
Drug: OCC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCC group (oxycodone: 1.5 mg/kg)
Trial: 37844986
Drug: Sufentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil group (sufentanil: 2 µg/kg)
Trial: 37844986
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including flurbiprofen 50 mg and ondansetron 16 mg)
Trial: 37845427
Drug: Idarucizumab (2×2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (2×2.5 g/50 ml) in group A
Trial: 37845427
Drug: Idarucizumab (2×2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (2×2.5 g/50 ml) in group B
Trial: 37845511
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg every 4 weeks for 12 months
Trial: 37845511
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg
Trial: 38324483
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg resmetirom
Trial: 38324483
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg resmetirom
Trial: 37845512
Drug: Open-label 100
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label 100 mg resmetirom
Trial: 37845608
Drug: Adjuvanted recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted recombinant glycoprotein E subunit herpes zoster vaccine (RZV)
Trial: 37845612
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of 0.2 ml colostrum every 3 hours for 5 consecutive days.
Trial: 37845612
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of sterile water (control group).
Trial: 37845696
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (pemetrexed plus cisplatin/carboplatin, C)
Trial: 37846080
Drug: Investigator-chosen chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-chosen chemotherapy (paclitaxel, docetaxel, or irinotecan)
Trial: 37846462
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 and 1.0 mg/kg)
Trial: 37846724
Drug: TAK-003 (Qdenga®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, administered during the second half of its 24-month shelf-life
Trial: 37846845
Drug: Early relapse
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early relapse within 18 months (ER18) after initial treatment
Trial: 37846935
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Oxygen (HFNO) treatment
Trial: 37847131
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT)
Trial: 37847131
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy (EVT) without intravenous thrombolysis (IVT)
Trial: 37847288
Drug: Hemp supplementation
RxNorm normalized name: hemp
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp supplementation (60 g/d containing 40 g protein and 9 g oil)